New Agent for Biliary Tract Cancer Approved

This post was originally published on Medscape

You will shortly be re-directed to the publisher's website

Zanidatamab is the first agent approved specifically for advanced, HER2-positive second-line biliary tract cancer.
Medscape Medical News